Enhancements to angioplasty for peripheral arterial occlusive disease: systematic review, cost-effectiveness assessment and expected value of information analysis

Emma L Simpson, Benjamin Kearns, Matthew D Stevenson, Anna J Cantrell, Chris Littlewood and Jonathan A Michaels*

The University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK

*Corresponding author

Declared competing interests of authors: none

Published February 2014
DOI: 10.3310/hta18100

Scientific summary

Enhancements to angioplasty for peripheral arterial occlusive disease
Health Technology Assessment 2014; Vol. 18: No. 10
DOI: 10.3310/hta18100

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Peripheral arterial occlusive disease (PAD) is a cause of major morbidity in the UK. There have been rapid technological developments aimed at improving the short- and long-term results of percutaneous transluminal balloon angioplasty (PTA).

Objectives

This report aimed to assess current evidence on the clinical effectiveness and cost-effectiveness of additional techniques designed to improve the results of standard transluminal balloon angioplasty for PAD, to develop a health economic model to assess cost-effectiveness and to identify areas where further primary research is needed.

Data sources

The following electronic databases were searched from inception to 2011: MEDLINE; MEDLINE In-Process & Other Non-Indexed Citations (Ovid); EMBASE (Ovid); The Cochrane Library; Cumulative Index to Nursing and Allied Health Literature (CINAHL); Science Citation Index (via ISI Web of Science); Social Science Citation Index (via ISI Web of Science); Conference Proceedings Citation Index – Science (CPCI-S) (via ISI Web of Science); UK Clinical Research Network Portfolio Database; Current Controlled Trials; and ClinicalTrials.gov. Searches were conducted between May and October 2011.

Methods

Systematic reviews were conducted of clinical effectiveness and cost-effectiveness of enhancement to angioplasty. Additional focused searches were conducted on the natural history and quality of life (QoL) for PAD.

The population was participants with symptomatic PAD undergoing endovascular treatment for disease distal to the inguinal ligament. Interventions were techniques used as an adjunct to, or as a replacement for, balloon angioplasty in the peripheral circulation. Conventional PTA was the main comparator. An expert group of clinicians assisted in the identification of relevant technologies, known trials and important outcome measures. Outcomes included measures of clinical effectiveness, restenosis and the need for reintervention, and costs. Data were extracted from randomised controlled trials (RCTs), which were quality assessed using standard criteria.

A discrete-event simulation model was developed to assess the relative cost-effectiveness of the interventions from a NHS perspective over a lifetime. The patient populations of intermittent claudication (IC) and critical limb ischaemia (CLI) were modelled separately. Univariate and probabilistic sensitivity analyses were undertaken.
Results

In total, 40 RCTs were included, although many had small sample sizes. Significantly reduced restenosis rates were shown in meta-analyses of self-expanding stents (SES) (relative risk (RR) 0.67 [95% confidence interval (CI) 0.52 to 0.87]), endovascular brachytherapy (EVBT) (RR 0.63 [95% CI 0.48 to 0.83]) at 12 months and drug-coated balloons (DCBs) at 6 months (RR 0.40 [95% CI 0.23 to 0.69]), and single studies of stent-graft or drug-eluting stent (DES), compared with PTA; a single study showed improvement of DES versus bare-metal stents (BMSs). Compared with PTA, walking capacity was not significantly affected by cutting balloon, balloon-expandable stents or EVBT; in SES, there was evidence of improvement in walking capacity after up to 12 months.

The use of DCBs dominated both the assumed standard practice of PTA with bail-out BMSs and all other interventions because it lowered lifetime costs and improved QoL. These results were seen for both patient populations (IC and CLI). Sensitivity analyses showed that the results were robust to different assumptions about the clinical benefits attributable to the interventions, suggesting that the use of DCBs is cost-saving.

Discussion

Despite many studies being identified, there remains uncertainty in the results of the report. Clinically, there was evidence of a significant benefit to reducing restenosis rates for SES, stent-graft, EVBT and DCB compared with PTA and for DES compared with BMS. If it is assumed that patency translates into beneficial long-term clinical outcomes, then DCB and bail-out DES are most likely to be the cost-effective enhancements to PTA.

A RCT comparing current recommended practice (PTA with bail-out BMS) with DCB and bail-out DES could assess long-term follow-up and cost-effectiveness. Data relating patency status to the need for reintervention and to the probability of symptoms returning should be collected, as should health-related QoL measures [European Quality of Life-5 Dimensions (EQ-5D) and maximum walking distance].

Study registration

This study is registered as PROSPERO CRD42012002014.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.

‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 09/116/01. The contractual start date was in January 2011. The draft report began editorial review in July 2012 and was accepted for publication in December 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2014. This work was produced by Simpson et al under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professorial Research Associate, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk